FDA Approves Shockwave Coronary Intravascular Lithotripsy System
Shockwave Medical received a FDA premarket approval for its C2 coronary intravascular lithotripsy-based calcification remedy and announced its 2020 results, in line with expectations.
You may also be interested in...
The company expects the FDA to approve its intravascular lithotripsy system with the C2 coronary catheter in early 2021 based on results from the Disrupt CAD III study.
In an interview with Medtech Insight, co-author of The Digital Pill, Elgar Fleisch proselytized the benefits of digital health, explaining how particular innovations could solve problems in health care.
April and May were full of cardiovascular professional society conferences, yielding important new research results along with announcements of major new clinical trials. Here are a few of the highlights.